BioSpace News Archive

Acentrus Specialty™, a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, has finalized an agreement with Puma Biotechnology, Inc.

Cerecor Inc. announced the first patient has been enrolled in a proof-of-concept trial evaluating the safety and efficacy of the anti-LIGHT monoclonal antibody, CERC-002, in patients with COVID-19 cytokine storm-induced Acute Respiratory Distress Syndrome.

Antares Pharma, Inc., a pharmaceutical technology company, announced the first commercialization of the Company’s multi-dose pen platform launched in Europe.

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.

CVRx, Inc., a private medical device company, announced that the BeAT-HF phase III randomized clinical trial has completed enrollment in the post-market phase.

Invitae Corporation, a leading medical genetics company, announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Trinseo, a global materials solutions provider and manufacturer of plastics, latex binders, and synthetic rubber, announced the release of its 2020 Sustainability & Corporate Social Responsibility Report.

In the long-term follow-up study of Zolgensma ® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA 1,2,3 The RESPOND study aims to evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma Biogen continues to advance research in spinal muscular atrophy to address the needs of the community and provide additional data to inform treatment decisions CAMBRIDGE,

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that the first patients have been dosed in a Phase 1b/2a clinical trial to assess NM-002 in adults with short bowel syndrome (SBS).

Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the market close. Management will host a con